Tag: drugs

under the sea on ecstasy – octopuses on MDMA

 

octopus on ecstasy

An octopus explores its surroundings. After receiving ecstasy, octopuses become more social.

Have you ever wondered what would happen to an octopus on ecstasy? If you have, then you aren’t alone. Gul Dolen, a neuroscientist a Johns Hopkins University School of Medicine, had wondered the same thing.

She and Eric Edsinger, conducted a study on the effects of the drug ecstasy, also known as (+/−)-3,4-methylendioxymethamphetamine or MDMA, on the brains and behaviors of octopuses. They placed octopuses  a chamber and allowed them to explore on their own. The chamber was connected to two others, one containing a hidden octopus and another containing a strange object. They then compared the time the octopus spent with either the object or the second octopus. The octopus tended to gravitate toward the other animal but only if it was a female. If the second octopus was a male, it avoided the second creature. This was true for bothe male and female octopuses placed into the chamber.

Then they gave the octopus a hit of MDMA, by dunking it into a solution containing the drug to allow it to soak in through its gills. While on the drug they spent way more time with male octopus. Describing their behavior, Dolen says”

“They mashed themselves against one wall, very slowly extended one arm, touched the [other animal], and went back to the other side. But when they had MDMA, they had this very relaxed posture. They floated around, they wrapped their arms around the chamber, and they interacted with the other octopus in a much more fluid and generous way. They even exposed their [underside], where their mouth is, which is not something octopuses usually do.”

This was very unusual behavior for octopuses, which are known to live in solitude. MDMA appeared to make the animals more social in a way that mimics its effects in humans. After studying serotonin transporter proteins in humans and octopuses, the researchers found that the sequences had a 50% match. It is especially similar in the part of the protein where MDMA binds, and that is why they believe they see similar effects in behavior.

But, some scientists remain unconvinced. The researchers always administered the drug after the control, so their more exploratory behavior could just be due to them being more comfortable in their surroundings. Other scientists suggest that ecstasy may just be interfering with the animal’s ability to detect chemical information from potential mates.

 

new adrogen blocking drug approved for prostate cancer

From Elie Dolgin of Nature magazine covers the news:

Men with advanced prostate cancer now have another treatment option, thanks to the approval today by the US Food and Drug Administration (FDA) of a pill that blocks androgen-receptor signaling and prolongs patient survival.

“To see activity in a post-hormone treated, post-chemotherapy treated prostate cancer population with a drug that doesn’t have myelosuppression [a decrease in blood cell production] and does has a very favorable safety profile is extremely exciting,” says Howard Scher, a prostate cancer specialist at the Memorial Sloan-KetteringCancer Center in New York. “My patient who got the drug in July 2007 is still on it. I have chills actually. It’s pretty amazing.”

The newly approved agent—Xtandi (enzalutamide), developed by San Francisco’s Medivation and Japan’s Astellas Pharma—works by plugging up the receptors that bind androgens, including testosterone, to prevent those male hormones from fueling the growth of prostate cancer cells. In a phase 3 clinical trial involving around 1,200 men with prostate cancer that had spread despite prior chemo- and hormone-therapy, an international team led by Scher found that participants taking Xtandi lived a median of 18.4 months, compared to 13.6 months for those who received a placebo. The drug also significantly lowered levels of prostate-specific antigen and boosted the time of progression-free survival, with only minimal side effects of fatigue, diarrhea and rare seizures. The results were reported earlier this month in the New England Journal of Medicine.

Read the complete coverage here.

//iwhaurouzy.net/4/4535925